As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection–mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.

BackgroundLong COVID, also called post-acute sequelae of SARS-CoV-2 infection (PASC), is a multi-system syndrome affecting millions of people worldwide. Neur...

British Dental Journal - Association between periodontitis and susceptibility to COVID-19 in a sample of adult Egyptian patients with respiratory infection symptoms: a case-control study

Pediatric Research - Neurological and neurodevelopmental effects of Covid and MIS-C on children

Patients recovering from post-coronavirus disease 2019 (COVID-19) often experience cognitive dysfunction, including difficulties with focusing, conversation, or memory issues, which can persist for we...

The nervous system exhibits remarkable adaptability through neuroplasticity, which allows for structural and functional changes in response to intrinsic and extrinsic stimuli. This dynamic process und...

Patients recovering from post-coronavirus disease 2019 (COVID-19) often experience cognitive dysfunction, including difficulties with focusing, conversation, or memory issues, which can persist for weeks or even months after infection. Although the persistence of the SARS-CoV-2 spike protein has bee …

This randomized clinical trial investigates if evidence-based rehabilitation strategies improve cognitive symptoms in persons with long COVID.

Young, low risk patients with ongoing symptoms of covid-19 had signs of damage to multiple organs four months after initially being infected, a preprint study has suggested.1 Initial data from 201 pa...

Background Although the majority of patients suffering from COVID-19 (coronavirus disease 2019) did not require hospitalization, data on the persistence of pulmonary sequelae after a mild SARS-CoV-2 (...

Background This study aimed to identify phenotypes of long COVID symptoms in adults following Omicron infection and assess their association with health-related quality of life (HRQoL). Methods We ana...

IntroductionDespite extensive research, the pathogenesis and predispositions underlying long COVID (long-term coronavirus disease 2019) remain poorly underst...

The COVID-19 pandemic has revealed and intensified the vulnerability of individuals with pre-existing medical and behavioral conditions, notably those relate...

Background and ObjectivesCognitive disability—defined by the Behavioral Risk Factor Surveillance System (BRFSS) as serious difficulty concentrating, remembering, or making decisions because of a physi...

Background National register-based studies on the influence of dementia on COVID-19 infection and outcomes are scarce. This study aims to evaluate the risk of COVID-19 infection, hospitalization, and ...

Angiotensin-converting enzyme 2 (ACE2) is important for cardiac and renal development as well as appropriate perinatal growth. In addition, ACE2 has r…

Background and aim The COVID-19 pandemic has left a lasting imprint on immune function, particularly in the elderly—a population already vulnerable to immunosenescence. While acute and long-COVID immu...